NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Price, News & Analysis $2.80 +0.07 (+2.38%) Closing price 05/2/2025 03:58 PM EasternExtended Trading$2.88 +0.09 (+3.22%) As of 05/2/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Xenetic Biosciences Stock (NASDAQ:XBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xenetic Biosciences alerts:Sign Up Key Stats Today's Range$2.66▼$2.8550-Day Range$2.30▼$3.9952-Week Range$2.20▼$5.20Volume11,613 shsAverage Volume12,947 shsMarket Capitalization$4.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Read More… Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIO Stock News HeadlinesXenetic Biosciences (XBIO) Receives a Hold from H.C. WainwrightApril 10, 2025 | markets.businessinsider.comXenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2025 | finance.yahoo.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 3, 2025 | Stansberry Research (Ad)Xenetic Biosciences IncAugust 27, 2024 | money.usnews.com3XB0.SG,0P0001N0OC,0 (3XB0.SG)July 24, 2024 | finance.yahoo.comXenetic Biosciences Inc (XBIO)April 10, 2024 | investing.comXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 24, 2024 | finance.yahoo.comXenetic Dips on Full-Year ResultsMarch 22, 2024 | baystreet.caSee More Headlines XBIO Stock Analysis - Frequently Asked Questions How have XBIO shares performed this year? Xenetic Biosciences' stock was trading at $3.99 at the beginning of the year. Since then, XBIO shares have decreased by 29.9% and is now trading at $2.7950. View the best growth stocks for 2025 here. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences Inc (NASDAQ:XBIO) posted its quarterly earnings data on Tuesday, March, 18th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.48. The business earned $0.65 million during the quarter, compared to analysts' expectations of $0.18 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 49.51% and a negative net margin of 161.63%. When did Xenetic Biosciences' stock split? Xenetic Biosciences shares reverse split before market open on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenetic Biosciences investors own include FuelCell Energy (FCEL), OPKO Health (OPK), VBI Vaccines (VBIV), Bionano Genomics (BNGO), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). Company Calendar Last Earnings3/18/2025Today5/03/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIO CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees4Year Founded2011Profitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,140,000.00 Net Margins-161.63% Pretax Margin-161.59% Return on Equity-49.51% Return on Assets-43.99% Debt Debt-to-Equity RatioN/A Current Ratio6.97 Quick Ratio6.97 Sales & Book Value Annual Sales$2.50 million Price / Sales1.72 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.44Miscellaneous Outstanding Shares1,542,000Free Float1,315,000Market Cap$4.31 million OptionableNot Optionable Beta2.31 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:XBIO) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.